Chemistry:LY-266,097

From HandWiki
Short description: Chemical compound
LY-266,097
LY-266097 structure.png
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H23ClN2O2
Molar mass370.88 g·mol−1
3D model (JSmol)

LY-266,097 is a research ligand which acts as a potent and selective antagonist for the 5-HT2B receptor, with more than 100x selectivity over the related 5-HT2A and 5-HT2C receptor subtypes.[1] It has been used to study the role of the 5-HT2B receptor in modulating dopamine release in the brain,[2][3] as well as its involvement in other processes such as allodynia.[4]

References

  1. "Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls [corrected"]. Respiratory Research 21 (1): 25. January 2020. doi:10.1186/s12931-020-1275-8. PMID 31941499. 
  2. "The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity". Journal of Neurochemistry 114 (5): 1323–1332. September 2010. doi:10.1111/j.1471-4159.2010.06848.x. PMID 20534001. 
  3. "Differential control of dopamine ascending pathways by serotonin2B receptor antagonists: New opportunities for the treatment of schizophrenia". Neuropharmacology 109: 59–68. October 2016. doi:10.1016/j.neuropharm.2016.05.024. PMID 27260325. 
  4. "5-HT2B Receptor Antagonists Reduce Nerve Injury-Induced Tactile Allodynia and Expression of 5-HT2B Receptors". Drug Development Research 76 (1): 31–39. February 2015. doi:10.1002/ddr.21238. PMID 25620128.